The EMPEROR-Reduced trial has shown that empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure (HF) in patients …, The EMPEROR-Reduced trial has shown that empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure (HF) in patients …, Read More